 |
市场调查报告书
商品编码
1498656
全球炭疽疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Anthrax Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
预计到2032年，全球炭疽疫苗市场需求将从2023年的167.3亿美元达到近281.6亿美元的市场规模，2024-2032年研究期间的复合年增长率为5.96%。
炭疽疫苗是一种生物製剂，可提供针对引起炭疽的炭疽桿菌的免疫力。它主要用于高暴露风险的个人，例如军事人员、实验室工作人员和处理动物产品的个人。该疫苗以免疫系统为目标，产生针对细菌保护性抗原的抗体，从而提供针对感染的防御。它是生物防御和职业健康计划的重要组成部分。
市场动态
生物恐怖主义和生物战的持续威胁，加上炭疽自然爆发的可能性，凸显了炭疽疫苗接种作为公共卫生防范措施的至关重要性。这提高了人们对炭疽作为潜在生物安全威胁的认识，促使政府机构和国防组织储存炭疽疫苗并投资疫苗接种计划，从而提振了市场需求。疫苗开发和製造技术的进步促进了下一代炭疽疫苗的开发，其安全性得到改善，功效增强，剂量方案减少，从而推动了市场的采用和扩张。此外，增加政府对生物防御计划和新出现的传染病的资助和研究拨款，透过支持疫苗研究和开发工作来刺激市场成长。
此外，不断扩大的全球旅行和贸易网络增加了炭疽传播和传播的风险，推动了高风险地区和高风险族群（例如军事人员、急救人员和实验室工作人员）对炭疽疫苗的需求。此外，製药公司、政府机构和研究机构之间的策略伙伴关係和合作促进了疫苗生产的可扩展性、监管审批和全球分销，从而促进了市场成长。然而，潜在的副作用和有限的意识可能会挑战未来几年的市场成长。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球炭疽疫苗市场的各个细分市场进行了包容性评估。炭疽疫苗产业的成长和趋势为本研究提供了整体方法。
市场区隔
炭疽疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。
按类型
- 无细胞 PA 疫苗（吸收炭疽疫苗 (AVA)、沉淀炭疽疫苗 (AVP)）
- 减毒活疫苗
按申请
- 兽医用途
- 人类使用
按最终用途
- 兽医医院和诊所
- 医院及诊所
- 其他
区域分析
本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲炭疽疫苗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。炭疽疫苗市场的主要参与者包括Altimmune Inc.、Agrovet、Bayer AG、Bavarian Nordic、Biogenesis Bago SA、Ceva Sante Animale、Colondo Serum Company、Emergent BioSolutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Solutions、Elusys Therapeutics Inc.、IndianImmunologicals Ltd.、Intervac (PVT) Ltd、 JOVAC、Merck Co Inc.、Proton Biopharma Ltd。和其他发展。
如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
目录
第一章：前言
- 报告说明
- 客观的
- 目标受众
- 独特的销售主张 (USP) 和产品
- 研究范围
- 研究方法论
- 市场研究过程
- 市场研究方法论
第 2 章：执行摘要
- 市集亮点
- 全球市场概况
第 3 章：炭疽疫苗 - 产业分析
- 简介 - 市场动态
- 市场驱动因素
- 市场限制
- 机会
- 产业动态
- 波特五力分析
- 市场吸引力分析
- 按类型分類的市场吸引力分析
- 市场吸引力分析：依应用分类
- 按最终用途分類的市场吸引力分析
- 市场吸引力分析：按地区
第 4 章：价值链分析
- 价值链分析
- 原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
- 潜在买家名单
- 行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势
第 5 章：全球炭疽疫苗市场分析：按类型
- 按类型概述
- 按类型分析历史和预测数据
- 无细胞 PA 疫苗（吸收炭疽疫苗 (AVA)、沉淀炭疽疫苗 (AVP)）
- 减毒活疫苗
第 6 章：全球炭疽疫苗市场分析：依应用分类
- 概述：按应用
- 历史与预测资料分析：按应用分类
- 兽医用途
- 人类使用
第 7 章：全球炭疽疫苗市场分析：依最终用途分类
- 按最终用途分类的概述
- 按最终用途分类的历史和预测资料分析
- 兽医医院和诊所
- 医院及诊所
- 其他
第 8 章：全球炭疽疫苗市场分析：依地理位置
- 区域展望
- 介绍
- 北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
- 欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
- 亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
- 拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
- 中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析
第 9 章：炭疽疫苗公司的竞争格局
- 炭疽疫苗市场竞争
- 伙伴关係/协作/协议
- 併购
- 新产品发布
- 其他发展
第 10 章：公司简介
- 顶级公司市占率分析
- 市场集中度
- Altimmune Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Agrovet
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Bayer AG
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Bavarian Nordic
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Biogenesis Bago SA
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Ceva Sante Animale
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Colondo Serum Company
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Emergent BioSolutions
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Elusys Therapeutics Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Indian Immunologicals Ltd.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Intervac (PVT) Ltd
- 公司简介
- 公司收入
- 产品
- 最近的发展
- JOVAC
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Merck Co Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Proton Biopharma Ltd
- 公司简介
- 公司收入
- 产品
- 最近的发展
註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内
The global demand for Anthrax Vaccine Market is presumed to reach the market size of nearly USD 28.16 Billion by 2032 from USD 16.73 Billion in 2023 with a CAGR of 5.96% under the study period 2024-2032.
The anthrax vaccine is a biological preparation that provides immunity against Bacillus anthracis, which causes anthrax. It is primarily used for individuals at high risk of exposure, such as military personnel, laboratory workers, and individuals handling animal products. The vaccine targets the immune system to generate antibodies against the bacterium's protective antigen, thereby providing defense against infection. It is a crucial component in biodefense and occupational health programs.
MARKET DYNAMICS
The persistent threat of bioterrorism and biological warfare, coupled with the potential for natural outbreaks of anthrax, underscores the critical importance of anthrax vaccination as a public health preparedness measure. This heightened awareness of anthrax as a potential biosecurity threat drives government agencies and defense organizations to stockpile anthrax vaccines and invest in vaccination programs, bolstering market demand. Advancements in vaccine development and manufacturing technologies have led to the development of next-generation anthrax vaccines with improved safety profiles, enhanced efficacy, and reduced dosage regimens, driving market adoption and expansion. Additionally, increasing government funding and research grants for biodefense initiatives and emerging infectious diseases stimulate market growth by supporting vaccine research and development efforts.
Moreover, expanding global travel and trade networks increase the risk of anthrax transmission and dissemination, driving demand for anthrax vaccines in high-risk regions and among at-risk populations, such as military personnel, first responders, and laboratory workers. Furthermore, strategic partnerships and collaborations between pharmaceutical companies, government agencies, and research institutions facilitate vaccine production scalability, regulatory approvals, and global distribution, fostering market growth. However, potential side effects and limited awareness may challenge the market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anthrax Vaccine. The growth and trends of Anthrax Vaccine industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Anthrax Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- Cell Free PA Vaccine (Anthrax Vaccine Absorbed (AVA), Anthrax Vaccine Precipitated (AVP))
- Live Attenuated Vaccine
By Application
- Veterinary Use
- Human Use
By End-use
- Veterinary Hospitals & Clinics
- Hospital & Clinics
- Other
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Anthrax Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anthrax Vaccine market include Altimmune Inc., Agrovet, Bayer AG, Bavarian Nordic, Biogenesis Bago SA, Ceva Sante Animale, Colondo Serum Company, Emergent BioSolutions, Elusys Therapeutics Inc., Indian Immunologicals Ltd., Intervac (PVT) Ltd, JOVAC, Merck Co Inc., Proton Biopharma Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. ANTHRAX VACCINE - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY TYPE
- 5.1. Overview By Type
- 5.2. Historical and Forecast Data Analysis By Type
- 5.3. Cell Free PA Vaccine (Anthrax Vaccine Absorbed (AVA), Anthrax Vaccine Precipitated (AVP)) Historic and Forecast Sales By Regions
- 5.4. Live Attenuated Vaccine Historic and Forecast Sales By Regions
6. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY APPLICATION
- 6.1. Overview By Application
- 6.2. Historical and Forecast Data Analysis By Application
- 6.3. Veterinary Use Historic and Forecast Sales By Regions
- 6.4. Human Use Historic and Forecast Sales By Regions
7. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY END-USE
- 7.1. Overview By End-use
- 7.2. Historical and Forecast Data Analysis By End-use
- 7.3. Veterinary Hospitals & Clinics Historic and Forecast Sales By Regions
- 7.4. Hospital & Clinics Historic and Forecast Sales By Regions
- 7.5. Other Historic and Forecast Sales By Regions
8. GLOBAL ANTHRAX VACCINE MARKET ANALYSIS BY GEOGRAPHY
- 8.1. Regional Outlook
- 8.2. Introduction
- 8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
- 8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
- 8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
- 8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
- 8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ANTHRAX VACCINE COMPANIES
- 9.1. Anthrax Vaccine Market Competition
- 9.2. Partnership/Collaboration/Agreement
- 9.3. Merger And Acquisitions
- 9.4. New Product Launch
- 9.5. Other Developments
10. COMPANY PROFILES OF ANTHRAX VACCINE INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Market Concentration Rate
- 10.3. Altimmune Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
- 10.4. Agrovet
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
- 10.5. Bayer AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
- 10.6. Bavarian Nordic
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
- 10.7. Biogenesis Bago SA
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
- 10.8. Ceva Sante Animale
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
- 10.9. Colondo Serum Company
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
- 10.10. Emergent BioSolutions
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
- 10.11. Elusys Therapeutics Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
- 10.12. Indian Immunologicals Ltd.
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
- 10.13. Intervac (PVT) Ltd
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
- 10.14. JOVAC
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
- 10.15. Merck Co Inc.
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
- 10.16. Proton Biopharma Ltd
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers: Impact Analysis
- Restraints: Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- Analysis By Type (USD MN)
- Cell Free PA Vaccine (Anthrax Vaccine Absorbed (AVA), Anthrax Vaccine Precipitated (AVP)) Market Sales By Geography (USD MN)
- Live Attenuated Vaccine Market Sales By Geography (USD MN)
- Analysis By Application (USD MN)
- Veterinary Use Market Sales By Geography (USD MN)
- Human Use Market Sales By Geography (USD MN)
- Analysis By End-use (USD MN)
- Veterinary Hospitals & Clinics Market Sales By Geography (USD MN)
- Hospital & Clinics Market Sales By Geography (USD MN)
- Other Market Sales By Geography (USD MN)
- Global Anthrax Vaccine Market Sales By Geography (USD MN)
- North America Market Analysis (USD MN)
- United States Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate By Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Anthrax Vaccine Report
- Market Research Process
- Market Research Methodology
- Global Anthrax Vaccine Market Size, By Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis By Type
- Market Attractiveness Analysis By Application
- Market Attractiveness Analysis By End-use
- Market Attractiveness Analysis By Region
- Value Chain Analysis
- Global Market Analysis By Type (USD MN)
- Cell Free PA Vaccine (Anthrax Vaccine Absorbed (AVA), Anthrax Vaccine Precipitated (AVP)) Market Sales By Geography (USD MN)
- Live Attenuated Vaccine Market Sales By Geography (USD MN)
- Global Market Analysis By Application (USD MN)
- Veterinary Use Market Sales By Geography (USD MN)
- Human Use Market Sales By Geography (USD MN)
- Global Market Analysis By End-use (USD MN)
- Veterinary Hospitals & Clinics Market Sales By Geography (USD MN)
- Hospital & Clinics Market Sales By Geography (USD MN)
- Other Market Sales By Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Company Market Share Analysis
![炭疽疫苗市场- 按类型（无细胞PA 疫苗[吸收、沉淀]、减毒活疫苗）、应用（人类使用、兽医使用）、最终用途（兽医医院和诊所、医院和诊所）和预测（2024 年- 2032 年） ）](/sample/img/cover/42/1532492.png)
